Instrument Inactif

Communiqués Histogen Inc.

Actions

HSTO.Q

US43358Y2028

Sociétés holdings

Communiqués

18/04/24	Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering	AQ
14/12/23	Histogen Announces Second Adjournment of Special Meeting of Stockholders	AQ
05/12/23	Histogen Announces Adjournment of Special Meeting of Stockholders	AQ
10/11/23	Histogen: Q3 Earnings Snapshot	AQ
18/09/23	Histogen Announces Board Approval of Complete Liquidation and Dissolution	AQ
15/08/23	Histogen : Change in Certifying Accountants - Form 8-K	PU
05/07/23	Histogen to Explore Strategic Alternatives	AQ
21/06/23	HISTOGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
11/05/23	Histogen: Q1 Earnings Snapshot	AQ
11/05/23	Histogen Reports First Quarter 2023 Results and Provides Business Update	AQ
20/04/23	Histogen Announces Online Publication in the Journal of Investigative Dermatology	AQ
03/04/23	Histogen : Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases - Form 8-K	PU
03/04/23	HISTOGEN INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
03/04/23	Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University	GL
16/03/23	Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use	GL
14/03/23	HISTOGEN INC. : Change in Directors or Principal Officers (form 8-K)	AQ
09/03/23	HISTOGEN INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
09/03/23	Histogen Reports Year-End 2022 Results and Provides Business Update	GL
27/02/23	Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	AQ
19/01/23	Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration	AQ
03/01/23	HISTOGEN INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
03/01/23	Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer	AQ
02/12/22	HISTOGEN INC. : Other Events (form 8-K)	AQ
10/11/22	Histogen: Q3 Earnings Snapshot	AQ
10/11/22	HISTOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ